New player in Biotech

DISCO Pharmaceuticals, a trailblazing biotech company at the forefront of cancer research, has officially embarked on its journey following a successful EUR 20 million seed financing round.
The company specializes in unlocking the surfaceome of cancer cells, utilizing transformative technology that provides a comprehensive map of the cancer cell surface and identifies novel druggable targets.

Founded in May 2022 as a spin-off from ETH Zürich, DISCO boasts a team of experts from ETH, the University of Cologne, and Stanford University. Led by CEO Roman Thomas, the team brings a wealth of knowledge in surface proteomics and oncology from various sectors, including academia, biotech, and pharma.

DISCO's groundbreaking technology addresses limitations in current oncology treatments by identifying proteins and protein communities across the entire cancer cell surface. This scalable approach aims to offer target candidates for both mono- and bi-specific antibodies, potentially revolutionizing the development of cancer-selective therapies with increased efficacy and reduced side effects.

Having already achieved a significant milestone by mapping the surfaceome of Small Cell Lung Cancer (SCLC), DISCO is actively developing proprietary antibody-based treatments for this challenging cancer type. The company is also focusing on Microsatellite-Stable Colorectal Cancer, an indication associated with high unmet medical needs.

Supported by a notable investor syndicate, including Sofinnova Partners, Panakes Partners, M Ventures, and AbbVie Ventures, DISCO Pharmaceuticals is set to transform cancer care by expanding the target space in oncology through its disruptive surfaceome discovery engine. The company's commitment to improving outcomes for patients underscores its dedication to innovation in oncology treatment.
For more information visit external pageDISCO Pharmaceuticals – The surfaceome companycall_made.